X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (737) 737
humans (735) 735
male (506) 506
esomeprazole (499) 499
female (492) 492
middle aged (405) 405
proton pump inhibitors (358) 358
adult (352) 352
omeprazole (352) 352
gastroenterology & hepatology (324) 324
aged (274) 274
pharmacology & pharmacy (267) 267
treatment outcome (265) 265
esomeprazole - therapeutic use (224) 224
esomeprazole - adverse effects (206) 206
esomeprazole - administration & dosage (203) 203
proton pump inhibitors - therapeutic use (197) 197
gastroesophageal reflux - drug therapy (193) 193
proton pump inhibitors - adverse effects (177) 177
lansoprazole (172) 172
drug therapy, combination (155) 155
anti-ulcer agents - therapeutic use (141) 141
helicobacter pylori (134) 134
gastroesophageal-reflux disease (132) 132
helicobacter infections - drug therapy (131) 131
double-blind method (129) 129
gastroesophageal reflux (129) 129
proton pump inhibitors - administration & dosage (124) 124
rabeprazole (123) 123
proton pump inhibitor (122) 122
medicine & public health (118) 118
anti-ulcer agents - administration & dosage (116) 116
therapy (111) 111
young adult (109) 109
anti-ulcer agents - adverse effects (108) 108
management (108) 108
prospective studies (108) 108
adolescent (107) 107
efficacy (105) 105
pantoprazole (105) 105
pharmacokinetics (100) 100
internal medicine (96) 96
dose-response relationship, drug (94) 94
care and treatment (93) 93
double-blind (93) 93
risk factors (92) 92
aged, 80 and over (91) 91
drug administration schedule (90) 90
abridged index medicus (87) 87
medicine, general & internal (85) 85
drug therapy (81) 81
gastroesophageal reflux disease (81) 81
anti-bacterial agents - therapeutic use (80) 80
pharmacology/toxicology (79) 79
erosive esophagitis (78) 78
infection (78) 78
metaanalysis (78) 78
risk (78) 78
drug interactions (76) 76
clinical trials (74) 74
dosage and administration (72) 72
omeprazole - adverse effects (72) 72
helicobacter pylori - drug effects (71) 71
symptoms (69) 69
time factors (67) 67
clarithromycin (65) 65
aspirin (63) 63
omeprazole - therapeutic use (63) 63
amoxicillin (60) 60
cross-over studies (60) 60
health aspects (60) 60
nonsteroidal antiinflammatory drugs (60) 60
eradication (59) 59
proton-pump inhibitors (59) 59
amoxicillin - therapeutic use (58) 58
safety (58) 58
triple therapy (57) 57
administration, oral (56) 56
hydrogen-ion concentration (56) 56
prevention (56) 56
esophagitis (55) 55
ulcers (55) 55
anti-inflammatory agents, non-steroidal - adverse effects (54) 54
analysis (53) 53
gerd (53) 53
research (53) 53
esomeprazole - pharmacology (52) 52
levofloxacin (52) 52
anti-bacterial agents - administration & dosage (50) 50
gastroenterology (50) 50
omeprazole - administration & dosage (50) 50
proton pump inhibitors - pharmacology (50) 50
ticlopidine - analogs & derivatives (50) 50
clopidogrel (49) 49
follow-up studies (49) 49
helicobacter infections (49) 49
2-pyridinylmethylsulfinylbenzimidazoles (48) 48
heartburn (48) 48
pharmacotherapy (48) 48
anti-bacterial agents - adverse effects (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (849) 849
French (11) 11
Spanish (7) 7
German (5) 5
Chinese (3) 3
Japanese (3) 3
Dutch (2) 2
Russian (2) 2
Bulgarian (1) 1
Korean (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 05/2011, Volume 305, Issue 19, pp. 1969 - 1977
Journal Article
CMAJ, ISSN 0820-3946, 11/2011, Volume 183, Issue 16, pp. 1835 - 1843
Background: Patients prescribed antiplatelet treatment to prevent recurrent acute myocardial infarction are often also given a selective serotonin reuptake... 
DEPRESSION | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | ANTIDEPRESSANTS | CLOPIDOGREL | EVENTS | PROGNOSIS | DRUGS | ELDERLY-PATIENTS | ASPIRIN | Age Factors | Anemia - epidemiology | Angioplasty | Humans | Middle Aged | Citalopram - adverse effects | Male | Risk | Secondary Prevention | Sertraline - adverse effects | Peptic Ulcer - epidemiology | Adrenal Cortex Hormones - therapeutic use | Renal Insufficiency - epidemiology | Aspirin - administration & dosage | Paroxetine - adverse effects | Paroxetine - administration & dosage | Fluvoxamine - administration & dosage | Canada - epidemiology | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Retrospective Studies | Drug Therapy, Combination | Heart Failure - epidemiology | Fluoxetine - adverse effects | Platelet Aggregation Inhibitors - adverse effects | Hypoglycemic Agents - therapeutic use | Hemorrhage - epidemiology | Risk Factors | Serotonin Uptake Inhibitors - adverse effects | Anticoagulants - therapeutic use | Antihypertensive Agents - therapeutic use | Fluvoxamine - adverse effects | Ticlopidine - analogs & derivatives | Citalopram - administration & dosage | Sertraline - administration & dosage | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Sex Factors | Aged | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Neoplasms - epidemiology | Cohort Studies | Aggregation | Complications and side effects | Blood platelets | Patient outcomes | Serotonin uptake inhibitors | Dosage and administration | Drug therapy | Hemorrhage | Heart attack | Risk factors | Studies | Side effects | Heart attacks | Inhibitor drugs | Index Medicus | Abridged Index Medicus | Research
Journal Article
Circulation, ISSN 0009-7322, 08/2013, Volume 128, Issue 8, pp. 845 - 853
BACKGROUND—Proton pump inhibitors (PPIs) are gastric acid–suppressing agents widely prescribed for the treatment of gastroesophageal reflux disease. Recently,... 
dimethylarginine dimethylaminohydrolase | endothelium | proton pump inhibitors | nitric oxide | N,N dimethylarginine | N dimethylarginine | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | ENDOTHELIAL DYSFUNCTION | MYOCARDIAL-INFARCTION | NITRIC-OXIDE SYNTHASE | ACID SUPPRESSION | ADMA | DIMETHYLAMINOHYDROLASE DDAH | PERIPHERAL VASCULAR DISEASE | CORONARY-HEART-DISEASE | STAGE RENAL-DISEASE | ARTERY-DISEASE | Proton Pump Inhibitors - pharmacology | Humans | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Endothelium, Vascular - drug effects | Male | Arginine - analogs & derivatives | Esomeprazole - therapeutic use | Cardiovascular Diseases - epidemiology | Nitric Oxide Synthase Type III - metabolism | Gastroesophageal Reflux - drug therapy | Disease Models, Animal | Amidohydrolases - metabolism | Proton Pump Inhibitors - adverse effects | Cardiovascular Diseases - metabolism | Mice, Inbred C57BL | Risk Factors | Cells, Cultured | Biomarkers - blood | Proton Pump Inhibitors - therapeutic use | Animals | Lansoprazole - adverse effects | Endothelium, Vascular - metabolism | Arginine - blood | Lansoprazole - pharmacology | Endothelium, Vascular - pathology | Mice | Vasodilation - drug effects | Lansoprazole - therapeutic use | Gastroesophageal reflux | Complications and side effects | Usage | Care and treatment | Patient outcomes | Proton pump inhibitors | Cardiovascular diseases | Drug therapy | Health aspects | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9573, pp. 1621 - 1626
Summary Background Guidelines on pain management recommend that patients at risk of ulcers receive either a cyclo-oxygenase (COX 2) inhibitor or a... 
Internal Medicine | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NSAID | CYCLOOXYGENASE-2 INHIBITORS | ARTHRITIS PATIENTS | NAPROXEN | COMPLICATIONS | HELICOBACTER-PYLORI | PEPTIC-ULCER | CELECOXIB | Pyrazoles - therapeutic use | Humans | Esomeprazole - adverse effects | Male | Secondary Prevention | Osteoarthritis - drug therapy | Esomeprazole - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Female | Drug Therapy, Combination | Pyrazoles - adverse effects | Anti-Ulcer Agents - therapeutic use | Double-Blind Method | Proton Pump Inhibitors | Risk Factors | Anti-Ulcer Agents - adverse effects | Peptic Ulcer Hemorrhage - chemically induced | Treatment Outcome | Celecoxib | Peptic Ulcer Hemorrhage - therapy | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Sulfonamides - adverse effects | Aged | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Prevention | Complications and side effects | COX-2 inhibitors | Relapse | Gastrointestinal bleeding | Peptic ulcer | Proton pump inhibitors | Dosage and administration | Drug therapy | Diseases | Drugs | Medical research | Physical examinations | Hospitals | Analgesics | Ulcers | Terminal illnesses | Clinical trials | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 03/2015, Volume 41, Issue 6, pp. 581 - 589
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 6/2013, Volume 71, Issue 6, pp. 1635 - 1643
The metabolism of pazopanib is primarily mediated by CYP3A4. The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its... 
Medicine & Public Health | Ketoconazole | Esomeprazole | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | CYP3A4 | Pazopanib | RABEPRAZOLE | HEALTHY-SUBJECTS | 24-H | TRIAL | ONCOLOGY | PHARMACOLOGY & PHARMACY | INHIBITOR | PHASE-I | DRUG-INTERACTION | Neoplasms - metabolism | Proton Pump Inhibitors - pharmacology | Esomeprazole - administration & dosage | Cytochrome P-450 CYP3A | Ketoconazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Male | Ketoconazole - pharmacology | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Angiogenesis Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Pyrimidines - administration & dosage | Angiogenesis Inhibitors - pharmacokinetics | Sulfonamides - pharmacokinetics | Neoplasms - drug therapy | Cytochrome P-450 CYP3A Inhibitors | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Aged | Ketoconazole - adverse effects | Sulfonamides - administration & dosage | Care and treatment | Metabolites | Analysis | Cytochrome P-450 | Tumors | Antiulcer drugs | Index Medicus
Journal Article
Journal Article
Journal Article
Stroke, ISSN 0039-2499, 03/2015, Volume 46, Issue 3, pp. 722 - 731
BACKGROUND AND PURPOSE—There is controversy and little information about whether individual proton pump inhibitors (PPIs) differentially alter the... 
LANSOPRAZOLE | drug interactions | PROPENSITY SCORE | CARDIOVASCULAR EVENTS | CORONARY | OMEPRAZOLE | stroke | CLINICAL NEUROLOGY | pharmacoepidemiology | proton pump inhibitors | CONCOMITANT USE | platelet aggregation inhibitors | cohort studies | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | OUTCOMES | Medicaid | JAPANESE PATIENTS | ARTERY-DISEASE | Rabeprazole - adverse effects | Esomeprazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Male | Risk | Drug Therapy, Combination - adverse effects | Stroke - chemically induced | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Ticlopidine - administration & dosage | Female | Stroke - epidemiology | Retrospective Studies | Brain Ischemia - chemically induced | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Data Interpretation, Statistical | Stroke - prevention & control | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Proportional Hazards Models | Omeprazole - adverse effects | Brain Ischemia - prevention & control | Ticlopidine - analogs & derivatives | Lansoprazole - adverse effects | Aged | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Rabeprazole - administration & dosage | Index Medicus | Pharmacoepidemiology | Stroke | Drug interactions | Cohort studies | Platelet aggregation inhibitors | Proton pump inhibitors
Journal Article
Journal Article